Matches in Wikidata for { <http://www.wikidata.org/entity/Q95172341> ?p ?o ?g. }
Showing items 1 to 37 of
37
with 100 items per page.
- Q95172341 description "clinical trial" @default.
- Q95172341 description "ensayo clínico" @default.
- Q95172341 description "ensayu clínicu" @default.
- Q95172341 description "klinisch onderzoek" @default.
- Q95172341 description "клінічне випробування" @default.
- Q95172341 description "临床试验" @default.
- Q95172341 name "A Study Evaluating Implementation Strategies for Cabotegravir (CAB)+ Rilpivirine (RPV) Long-acting (LA) Injectables for Human Immunodeficiency Virus (HIV)-1 Treatment in European Countries" @default.
- Q95172341 name "A Study Evaluating Implementation Strategies for Cabotegravir (CAB)+ Rilpivirine (RPV) Long-acting (LA) Injectables for Human Immunodeficiency Virus (HIV)-1 Treatment in European Countries" @default.
- Q95172341 type Item @default.
- Q95172341 label "A Study Evaluating Implementation Strategies for Cabotegravir (CAB)+ Rilpivirine (RPV) Long-acting (LA) Injectables for Human Immunodeficiency Virus (HIV)-1 Treatment in European Countries" @default.
- Q95172341 label "A Study Evaluating Implementation Strategies for Cabotegravir (CAB)+ Rilpivirine (RPV) Long-acting (LA) Injectables for Human Immunodeficiency Virus (HIV)-1 Treatment in European Countries" @default.
- Q95172341 prefLabel "A Study Evaluating Implementation Strategies for Cabotegravir (CAB)+ Rilpivirine (RPV) Long-acting (LA) Injectables for Human Immunodeficiency Virus (HIV)-1 Treatment in European Countries" @default.
- Q95172341 prefLabel "A Study Evaluating Implementation Strategies for Cabotegravir (CAB)+ Rilpivirine (RPV) Long-acting (LA) Injectables for Human Immunodeficiency Virus (HIV)-1 Treatment in European Countries" @default.
- Q95172341 P1132 Q95172341-7C500D88-EBEA-484F-BF09-489E6A7E50F4 @default.
- Q95172341 P1476 Q95172341-CEE81910-8778-4F78-A152-4F0915613A17 @default.
- Q95172341 P2899 Q95172341-765B5A52-9913-49C9-B4C1-BF15309B4C2A @default.
- Q95172341 P3098 Q95172341-AEA98B39-804F-44A9-A2E4-F887F3579A44 @default.
- Q95172341 P31 Q95172341-3DE62D37-41DA-44DB-970D-FD70F6AD671C @default.
- Q95172341 P580 Q95172341-626CC5FC-11A2-4078-9E40-279439A4FB33 @default.
- Q95172341 P582 Q95172341-C29482B0-7D83-440F-B9A4-356DB2EA5916 @default.
- Q95172341 P6099 Q95172341-0A7CB2A7-8A42-449D-B23A-42B940BE6576 @default.
- Q95172341 P767 Q95172341-B2DFD0CE-36E0-43F7-9195-C3A94FF0C96B @default.
- Q95172341 P8005 Q95172341-4FEC9A71-B26E-499C-8132-4C697A8C6015 @default.
- Q95172341 P8363 Q95172341-7842323C-FB5C-47FF-B9DE-13C012ADD3CB @default.
- Q95172341 P921 Q95172341-AFDE23D0-D943-430E-A1A3-E185B29674F3 @default.
- Q95172341 P1132 "+450" @default.
- Q95172341 P1476 "A Phase IIIb, Open-label, Hybrid Type III Trial Evaluating Implementation Strategies for Long-acting Cabotegravir Plus Long-acting Rilpivirine Every Two Months in HIV-1 Infected, Virologically Suppressed Adults in Select European Healthcare Settings" @default.
- Q95172341 P2899 "+18" @default.
- Q95172341 P3098 "NCT04399551" @default.
- Q95172341 P31 Q30612 @default.
- Q95172341 P580 "2020-09-18T00:00:00Z" @default.
- Q95172341 P582 "2022-02-25T00:00:00Z" @default.
- Q95172341 P6099 Q42824827 @default.
- Q95172341 P767 Q45135018 @default.
- Q95172341 P8005 Q76649614 @default.
- Q95172341 P8363 Q78089383 @default.
- Q95172341 P921 Q421547 @default.